Jason Rhodes

Jason Paul Rhodes is the founder of Disarm Therapeutics, Inc. (founded 2016) where the title held was Chairman from 2019 to 2020.
Mr. Rhodes is the founder of Dyne Therapeutics, Inc. (founded 2017) and holds the title of Chairman since 2018.
Mr. Rhodes was the founder of F-Prime Inc. (founded 2001) and held the title of Partner from 2001 to 2007.
Mr. Rhodes was the founder of Generation Bio Co. (founded 2016) and held the title of Director from 2025 to 2026.
Current jobs include Executive Chairman at Rectify Pharmaceuticals LLC; Director at Gemini Therapeutics Sub, Inc. since 2016; Director at Accent Therapeutics, Inc. since 2017; Director at Be Biopharma, Inc.; Director at K36 Therapeutics, Inc.; Partner at Atlas Venture Advisors, Inc. since 2014; Partner at Atlas Venture Life Science Advisors LLC since 2014; and Board Member at AAVantgarde Bio Srl.
Former jobs included Chief Executive Officer & Director at Raze Therapeutics, Inc.; Independent Director at Bicycle Therapeutics Plc from 2015 to 2019; Director at Zyngenia, Inc.; Director at New England Venture Capital Association, Inc.; Independent Director at Replimune Group, Inc. from 2015 to 2022; Director at Third Harmonic Bio, Inc.; Independent Director at Gemini Therapeutics, Inc. from 2016 to 2022; Chief Financial Officer at FORUM Pharmaceuticals, Inc.; Vice President of Business Development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010; President, Chief Financial Officer & Treasurer at Epizyme, Inc. from 2013 to 2014; Partner at F-Prime Inc. from 2001 to 2007.
Education includes an undergraduate degree from Yale University conferred in 1991, an MBA from The Wharton School of the University of Pennsylvania conferred in 1996, and a doctorate from Harvard Medical School conferred in 2004.